Patient group	Low risk	Intermediate risk	High risk
* Note: This treatment option is under clinical evaluation.
Premenopausal, ER-positive or PR-positive	None or tamoxifen	Tamoxifen plus chemotherapy, tamoxifen alone, ovarian ablation, GnRH analog*	Chemotherapy plus tamoxifen, chemotherapy plus ablation or GnRH analog*, chemotherapy plus tamoxifen plus ovarian ablation or GnRH*, or ovarian ablation alone or with tamoxifen or GnRH alone or with tamoxifen
Premenopausal, ER-negative or PR-negative	—	—	Chemotherapy
Postmenopausal, ER-positive or PR-positive	None or tamoxifen	Tamoxifen plus chemotherapy, tamoxifen alone	Tamoxifen plus chemotherapy, tamoxifen alone
Postmenopausal, ER-negative or PR-negative	—	—	Chemotherapy
Older than 70 years	None or tamoxifen	Tamoxifen alone, tamoxifen plus chemotherapy	Tamoxifen; consider chemotherapy if ER-negative or PR-negative